Merck & Co., Inc., Rahway, NJ, USARahway, New Jersey, United States
Disclosure information not submitted.
133 - Clesrovimab Efficacy through 6 Months during a Time of Changing SARS-CoV-2 Nonpharmaceutical Interventions (NPIs): Subgroup Analysis of the China Cohort in the Phase 2b/3 CLEVER Trial
Monday, October 20, 202512:25 PM - 12:30 PM US ET
